Group 1 - The core viewpoint of the report indicates that Hansoh Pharmaceutical (03692) is expected to have smooth sales in the second half of the year, with an $80 million upfront payment from Roche expected to be recognized by the end of 2025, which will facilitate the development of HS-20110 [1] - Innovating drugs are making significant progress in international markets, with Hansoh Pharmaceutical granting Roche exclusive global rights for HS-20110 outside Greater China, and Innovent Biologics (01801) collaborating with Takeda to advance new generation tumor immunotherapy (IO) and antibody-drug conjugates (ADC) [2] - The Hang Seng Healthcare Index underperformed the Hang Seng Index in October, declining by 11.1%, attributed to concerns over potential impacts of increased drug tariffs in the U.S. and the upcoming expiration of the patent for the weight-loss drug semaglutide in China in 2026 [1][2] Group 2 - The eleventh batch of national volume-based procurement in mainland China included 55 types of drugs, with major Hong Kong pharmaceutical companies like Hansoh Pharmaceutical, CSPC Pharmaceutical Group (01093), and China Biologic Products (01177) having products selected, but none of their core products were affected [3] - The collaboration with Roche is expected to enhance the development of HS-20110 due to Roche's extensive experience in ADC development, while the partnership with Takeda is anticipated to benefit both product development and sales due to Takeda's strong sales network in Japan and the U.S. [2]

Group 1 - The core viewpoint is that the Hong Kong Stock Connect Innovative Drug ETF has shown significant liquidity and growth in scale, with a recent net inflow of 56.08 million yuan and a total scale reaching 1.027 billion yuan [3] - The ETF's average daily trading volume over the past week was 133 million yuan, indicating strong investor interest [3] - The top ten weighted stocks in the CSI Hong Kong Stock Connect Innovative Drug Index account for 71.11% of the index, highlighting concentration in key players like WuXi Biologics and Innovent Biologics [3] Group 2 - Analysts suggest that the recent adjustment in the innovative drug sector from August to October is relatively benign, with no negative changes in the industry fundamentals [4] - The pharmaceutical sector is viewed as being at a relative bottom, providing strong safety margins and potential for upward movement [4] - The 2026 strategy for the pharmaceutical and biotechnology industry emphasizes that innovative drugs will remain a key investment theme due to their growing international status and significant market potential [4]

Core Viewpoint - The pharmaceutical and biotechnology sector shows mixed performance, with innovative drugs and CXO services performing well, while the medical device sector is expected to continue its recovery [4][5]. Group 1: Pharmaceutical Sector Performance - In the first three quarters of 2025, the pharmaceutical and biotechnology sector achieved revenue of 1,825.74 billion yuan (YOY -1.97%) and a net profit of 139.66 billion yuan (YOY -1.59%) [4]. - In Q3 2025, the sector generated revenue of 598.54 billion yuan (YOY +0.78%) and a net profit of 40.51 billion yuan (YOY +7.67%) [4]. - The gross profit margin for the pharmaceutical sector was 31.4% (YOY -1.4 percentage points), with a total gross profit of 573.45 billion yuan (YOY -6.1%) [4]. Group 2: Subsector Analysis - The chemical preparation sector saw a revenue decline of 0.82% in Q3 2025, but net profit increased by 5.05%, driven by strong performance from innovative drug companies [5]. - The medical device sector experienced significant revenue growth of 10.65% in Q3 2025, reflecting a recovery in domestic bidding processes [5]. - The CXO sub-sector showed robust performance with a revenue increase of 10.93% and a net profit increase of 47.90% in Q3 2025, indicating strong demand both domestically and internationally [5]. Group 3: Fund Holdings and Market Trends - In Q3 2025, the market value of pharmaceutical holdings in equity mutual funds was 11.93%, a decrease of 0.32 percentage points from the previous quarter [6]. - The top rising stocks in terms of market value among heavy holdings included Rongchang Biotechnology and BeiGene, which rose 18 and 13 ranks respectively [6]. - The number of funds holding top stocks like China National Pharmaceutical Group and Yingke Medical increased significantly, indicating growing interest in these companies [6].

Core Viewpoint - The Hong Kong stock market experienced fluctuations, but the biotechnology sector showed resilience, with leading stocks like BeiGene, Innovent Biologics, and 3SBio rebounding, while the Hong Kong Stock Connect Innovative Drug ETF (520880) demonstrated strong performance despite a slight decline at the end of the trading day [1][3]. Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) saw a net subscription of approximately 86 million yuan yesterday, accumulating over 300 million yuan in the past ten days, indicating strong investor interest in the innovative drug sector [3]. - The ETF opened lower but quickly rebounded, closing down 0.54% while managing to record a positive daily line, suggesting a slight advantage for bullish forces [1][3]. Technical Analysis - The ETF formed a "中" character candlestick, reflecting intense competition between bulls and bears, with a closing bullish line indicating that bullish momentum may be strengthening [1]. - The MACD indicator shows an expanding red bar, further confirming the potential increase in bullish momentum [1]. Fundamental Analysis - The innovative drug sector is experiencing a global rise and commercialization phase, driven by accelerated business development (BD) overseas, a dense pipeline of products, and supportive policies [3]. - According to Dongwu Securities, innovative drugs will remain a key investment theme through 2026, with significant growth expected in international standing, BD expansion, and a shift towards profitability [3]. ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) exclusively tracks innovative drug research companies, excluding CXO firms, ensuring a pure focus on innovation [4]. - The top ten holdings in the ETF account for over 71% of the index, highlighting the dominance of leading innovative drug companies [4][5]. - The ETF has a total market size exceeding 2 billion yuan as of November 3, with an average daily trading volume of 474 million yuan, making it the largest and most liquid ETF tracking this index [5].

Core Viewpoint - The Hong Kong stock market experienced fluctuations, but the biotechnology sector showed resilience, with leading stocks like BeiGene, Innovent Biologics, and 3SBio rebounding, while the Hong Kong Stock Connect Innovative Drug ETF (520880) demonstrated strong performance despite a slight decline at the end of the trading day [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) opened lower but quickly rebounded, ultimately closing down 0.54% while managing to record a positive daily line [1]. - The ETF's trading volume significantly increased, indicating potential new capital entering the market [1]. - The ETF's technical analysis showed a "中" character candlestick, reflecting intense competition between bulls and bears, with bullish momentum slightly prevailing [1]. Group 2: Fund Flows - The ETF saw a net subscription of nearly 86 million yuan yesterday, accumulating over 300 million yuan in the past ten days, indicating strong investor interest in the innovative drug sector [3]. - The current market position is considered attractive for allocation, as prior profit-taking has largely completed, and some leading stocks may have entered an absolute return zone [3]. Group 3: Industry Fundamentals - The fundamentals of the innovative drug sector remain positive, with accelerated business development (BD) overseas, a dense pipeline of products, and supportive policies contributing to a global rise and commercialization of domestic innovative drugs [3]. - According to Dongwu Securities, innovative drugs will remain a key investment theme through 2026, driven by the sector's improving international standing, explosive growth in BD, significant market capitalization potential, and a transition to profitability for many companies [3]. Group 4: ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) exclusively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three unique advantages: it is purely focused on innovative drug companies, has a high concentration of leading firms, and effectively manages tail risks by reducing the weight of less liquid stocks [4][5]. - As of early November, the ETF's total assets surpassed 2 billion yuan, making it the largest and most liquid ETF tracking this index [6].

Group 1 - The innovative drug sector has regained investor attention since the inclusion of innovative drugs in medical insurance negotiations, with significant capital inflow into the Hang Seng Innovative Drug ETF (520500) totaling 214 million yuan over four consecutive trading days [1] - The first version of the commercial insurance innovative drug catalog is set to be officially released on the first weekend of December 2025, with implementation starting on January 1, 2026 [1] - The National Healthcare Security Administration's announcement on November 4, 2025, regarding the successful conclusion of drug price negotiations has significantly boosted market confidence, potentially enhancing the payment landscape for high-value innovative drugs [1] Group 2 - The "Creating the Future: International Lung Cancer Frontier and Innovation Forum" held in Shanghai on November 2, 2025, gathered top lung cancer experts from multiple countries to address key challenges in lung cancer treatment, which may further promote the integration and development of innovative drug technologies [2] - The Hang Seng Innovative Drug ETF (520500) is currently the only ETF tracking the Hang Seng Innovative Drug Index, which includes companies involved in the research, development, and production of innovative drugs, emphasizing strong R&D capabilities [2] - The establishment of the commercial insurance innovative drug catalog is expected to provide a more flexible market access pathway for high-value innovative drugs, opening up market demand channels [2]

Core Insights - In October, the net value return of the GF CSI Hong Kong Innovative Drug ETF (QDII) decreased by 11.61% due to fluctuations in the Hong Kong stock market [1] - The fund's scale reached 24.889 billion yuan, with the top ten holdings including companies like Innovent Biologics, BeiGene, WuXi Biologics, and others [1] - The fund manager, Liu Jie, has over 10 years of experience in managing public funds since 2014 [1] Fund Performance - The GF CSI Hong Kong Innovative Drug ETF (QDII) reported a net value growth rate of -11.61% with a net value of 1.3337 yuan and a total scale of 24.889 billion yuan [2] - The GF CSI Hong Kong Innovative Drug ETF Initiated Link (QDII) C and A also experienced declines of over 11% in October, with net values of 1.3853 yuan and 1.3937 yuan respectively [2] - The largest holding, Innovent Biologics, saw a decline of 9.75% in October, while another major holding, CanSino Biologics, dropped over 19% [1]

Core Insights - The pharmaceutical industry is experiencing a structural change driven by the growth cycles of major products, with significant opportunities emerging in innovative drugs, medical devices, and consumer healthcare [3][6][31] - The demand for pharmaceuticals is expected to improve in 2026, supported by policies encouraging innovation and a recovery in domestic consumption [3][7] - The supply side of the pharmaceutical industry is characterized by high entry barriers due to patent protections and government regulations, which helps maintain a stable competitive environment [4][5] Group 1: Industry Trends - The aging population, urbanization, and changing disease patterns are making the pharmaceutical industry a perpetual growth sector [3] - The global pharmaceutical market has seen rapid expansion from 2009 to 2019, followed by a surge in demand due to COVID-19, and is now entering a phase of recovery and growth [3][6] - The Chinese pharmaceutical industry is expected to gradually produce world-class companies, with increasing recognition of Chinese innovative drug assets by multinational corporations (MNCs) [4][5] Group 2: Investment Opportunities - Opportunities in innovative drugs are highlighted, particularly in oncology, metabolic diseases, and autoimmune diseases, with a focus on next-generation therapies and precision medicine [6][31] - The demand for innovative drugs is expected to remain strong, with policies improving medical insurance payments and the upcoming launch of commercial insurance drug catalogs [7][31] - The medical device sector is anticipated to recover, with a focus on domestic demand and international expansion, particularly in areas with low domestic production rates [7][8] Group 3: Company Performance - Major pharmaceutical companies like Eli Lilly, AbbVie, and AstraZeneca are experiencing significant growth driven by key products, with Eli Lilly's Tirzepatide generating $24.8 billion in sales [12][15] - The report identifies specific companies such as Hengrui Medicine, Hansoh Pharmaceutical, and BeiGene as outperformers in the market, with strong pipelines and global competitiveness [7][8] - The report emphasizes the importance of mergers and acquisitions (M&A) and business development (BD) strategies for MNCs, with China becoming a significant source of projects for top global pharmaceutical companies [22][24]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [5]. Core Insights - The innovative drug and CXO sectors have shown strong performance, while the medical device sector is expected to continue its recovery [1]. - In the first three quarters of 2025, the pharmaceutical and biotechnology sector achieved revenues of CNY 18,257.4 billion (down 1.97% year-on-year) and a net profit of CNY 1,396.6 billion (down 1.59% year-on-year) [1]. - The third quarter of 2025 saw revenues of CNY 5,985.4 billion (up 0.78% year-on-year) and a net profit of CNY 405.1 billion (up 7.67% year-on-year) [1]. - The overall gross profit margin for the pharmaceutical sector was 31.4% (down 1.4 percentage points year-on-year) [1]. Summary by Sections Chemical Preparations Sector - In Q3 2025, the chemical preparations sector experienced a revenue decline of 0.82% year-on-year, but net profit increased by 5.05% [2]. - The growth is attributed to strong performance from leading innovative drug companies and increased sales from BD transactions [2]. Medical Devices Sector - The medical devices sector saw a significant revenue increase of 10.65% year-on-year in Q3 2025, reflecting a recovery in domestic bidding [2]. - The medical consumables sector faced challenges with a revenue decline of 0.50% due to policy impacts [2]. Medical Services Sector - The CXO sub-sector showed robust performance with a revenue increase of 10.93% year-on-year and a net profit increase of 47.90% in Q3 2025 [2]. - The hospital sector, however, faced pressure with a revenue decline of 1.19% and a net profit decline of 18.51% [2]. Fund Holdings in Pharmaceuticals - In Q3 2025, the proportion of public fund holdings in pharmaceuticals decreased to 11.93%, down 0.32 percentage points from the previous quarter [3]. - The top 20 stocks held by funds primarily include traditional pharmaceuticals, innovative drugs, and CXO sectors [3]. Investment Recommendations - The report recommends focusing on the innovative drug industry chain and innovative medical devices, highlighting specific companies such as BeiGene, WuXi AppTec, and Mindray Medical [3].

Group 1: Liquidity and Fund Performance - The Hong Kong Stock Connect Innovative Drug ETF managed by Harvest saw an intra-day turnover of 7.76%, with a transaction volume of 76.0143 million yuan [2] - Over the past year, the average daily transaction volume of the ETF reached 116 million yuan [2] - In the past week, the ETF's scale increased by 39.7287 million yuan, ranking first among comparable funds [2] - The latest share count for the ETF reached 1.046 billion shares [2] - The ETF experienced a net inflow of 14.1619 million yuan, with a total of 46.8442 million yuan net inflow over three of the last five trading days [2] Group 2: Valuation and Index Composition - The latest price-to-earnings ratio (PE-TTM) for the index tracked by the ETF is 31.84, which is in the 19.17th percentile over the past three years, indicating a valuation lower than 80.83% of the time in the last three years [2] - As of October 31, 2025, the top ten weighted stocks in the index include WuXi Biologics, Innovent Biologics, BeiGene, and others, collectively accounting for 71.11% of the index [2] Group 3: Policy and Market Outlook - The first version of the commercial insurance innovative drug directory is set to be released, with negotiations for the 2025 National Basic Medical Insurance Drug Directory concluding successfully [3] - A total of 120 domestic and foreign enterprises participated in the negotiations, with 127 drugs outside the directory involved in the bidding process [3] - The innovative drug industry is expected to remain in a golden development period, benefiting from advancements in clinical development and a rich pipeline of innovative drugs [3] - AI drug development and gene therapy technologies are anticipated to bring new breakthroughs in the coming years [3]